Thyrotropin Receptor Antibody, Serum

CPT: 83520
Print Share

Test Details


  • LATS
  • Long-acting Thyroid Stimulator
  • TBII
  • Thyrotropin-binding Inhibitory Immunoglobulin
  • TRAb
  • TSH Receptor Antibody
  • TSH Receptor-binding Inhibitory Immunoglobulin


Diagnosis of hyperthyroidism and Graves' disease


Electrochemiluminescence immunoassay (ECLIA)

Reference Interval

0.0−1.75 units/L

Additional Information

Thyrotropin-receptor antibody is an autoantibody to the thyroid cell receptor for thyroid-stimulating hormone. It can be demonstrated in 90% of patients with Graves' disease, and is the cause of the hyperthyroidism of that condition. The characterization of TRA resolved much confusion about long-acting thyroid stimulator (LATS) and LATS protector, which are both, in fact, thyroid-stimulating autoantibodies which simply behaved differently in animal test systems. These antibodies are present in 50% of euthyroid Graves' disease as well as hyperthyroid patients. They play a major role in the pathogenesis of Graves' disease. Detection of these antibodies is useful in prediction of neonatal hyperthyroidism and prediction of relapse of hyperthyroidism.

Specimen Requirements




0.8 mL

Minimum Volume

0.3 mL (Note: This volume does not allow for repeat testing.)


Red-top tube or gel-barrier tube


If tube other than a gel-barrier tube is used, transfer separated serum to a plastic transport tube.

Storage Instructions

Refrigerate; stable for three days. Stable frozen for one month.

Causes for Rejection

Citrate plasma specimen; samples collected in heparin or samples from patients on heparin therapy; lipemic or hemolyzed serum samples; improper labeling

Clinical Information

Special Instructions

This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.


Colvin RB, Bhan AK, McCluskey RT, eds. Diagnostic Immunopathology. New York, NY: Raven Press;1988.
Gupta MK. Recent advances in laboratory tests for autoantibodies to thyrotropin receptor protein in Graves' disease. Clin Lab Med. 1988 Jun; 8(2):303-323 (review). 3284698
Gupta MK. Thyrotropin receptor antibodies: Advances and importance of detection techniques in thyroid disease. Clin Biochem. 1992 Jun; 25(3):193-199. 1633635
McKenzie JM, Zakarija M. Clinical review 3: The clinical use of thyrotropin receptor antibody measurements. J Clin Endocrinol Metab. 1989 Dec; 69(6):1093-1096. 2685006
Morris JC 3rd, Hay ID, Nelson RE, Jiang NS. Clinical utility of thyrotropin-receptor antibody assays: Comparison of radioreceptor and bioassay methods. Mayo Clin Proc. 1988 Jul; 63(7):707-717. 2898572
Nakamura RM, Binder WL. Current concepts and diagnostic evaluation of autoimmune disease. Arch Pathol Lab Med. 1988 Sep; 112(9):869-877 (review). 3046557


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
010314 Thyrotropin Receptor Ab, Serum 5385-0 010317 Thyrotropin Receptor Ab, Serum IU/L 5385-0

For Providers

Please login to order a test.


© 2018  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at